title: Current and Emerging Therapies for Itch Management in Psoriasis.
abstract: Pruritus is a common and significant symptom among patients with psoriasis. Pruritus is often present beyond the borders of psoriatic plaques, and frequently affects the scalp and genital regions. Psoriatic itch may be severe and can profoundly affect quality of life and sleep, even in the context of mild-to-moderate disease. These features often make the treatment of psoriatic pruritus challenging. However, there are a variety of effective topical and systemic treatment modalities available to address this symptom. While there remains a need for treatments that specifically target psoriatic itch, newly licensed therapies including secukinumab, ixekizumab and apremilast have been shown to rapidly and effectively mediate itch reduction.
authors.affiliation: Department of Dermatology and Itch Center, Lewis Katz School of Medicine at Temple University, 3322 North Broad Street, Medical Office Building, Suite 212, Philadelphia, PA, 19140, USA.
authors.forename: Carolyn
authors.initials: C
authors.lastname: Stull
authors.affiliation: Department of Dermatology and Itch Center, Lewis Katz School of Medicine at Temple University, 3322 North Broad Street, Medical Office Building, Suite 212, Philadelphia, PA, 19140, USA.
authors.forename: Shoshana
authors.initials: S
authors.lastname: Grossman
authors.affiliation: Department of Dermatology and Itch Center, Lewis Katz School of Medicine at Temple University, 3322 North Broad Street, Medical Office Building, Suite 212, Philadelphia, PA, 19140, USA. Yosipog@gmail.com.
authors.forename: Gil
authors.initials: G
authors.lastname: Yosipovitch
mesh_terms: D000287:Administration, Topical; D000982:Antipruritics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010789:Phototherapy; D011537:Pruritus / Q000209:etiology / Q000628:therapy*; D011565:Psoriasis / Q000150:complications / Q000628:therapy*; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000982:Antipruritics; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents